XML 61 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Research, Collaboration and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue Recognized from Strategic Partnerships
Revenue recognized from the Company’s strategic partnerships is summarized as follows:
Year ended December 31,
202320222021
Jazz:
Recognition of licensing and technology transfer fee$— $375,000 $— 
Development support payments
52,61920,671 — 
Drug supply for ongoing studies
25,662 3,610 — 
Credit note for amendment of program(20,100)— — 
Other drug supply
13,350— — 
Atreca:
Recognition of licensing fee— 5,000 — 
BeiGene:
Milestone revenue— — 8,000 
Janssen:
Milestone revenue— — 8,000 
Iconic:
Partner revenue— — 5,000 
Research and development support and other payments4,481 8,201 5,680 
$76,012 $412,482 $26,680